Ann: P3 Trial of MSB's Cell Therapy in CHF Completes Recruitment, page-42

It is pretty inscrutable techinvestor.

The trialnow comprises two composite co-primaries - HF-MACE and TCE. Both are event driven.  

And so by moving the TCE events from secondaries to primaries you are in effect increasing the event rate.  So shortening the trial length. But the price you pay is that now significance is required on two primary outcomes. 

MSB haven’t updated the trial registration to reflect this change if indeed this is wha thas happened. https://clinicaltrials.gov/ct2/show/NCT02032004 

It is a complete mystery to why companies don’t wish to inform investors about wha tthey are doing with their trials. I suppose dumb investors can’t ask difficult questions.  But really this has now trained everyone up to believe that if anything unusual occurs during a clinical trial (that is referred to in some obscure way by the company)… just sell.